Nebula’s Warrant Amendment Actually Only Needs 50% Approval
by Kristi Marvin on 2020-01-06 at 3:43pm

As part of Nebula Acquisition Corp.’s (NEBU), announced deal this morning with Open Lending LLC, they included their intention to tender their warrants for $1.50 per whole warrant.  And further to that, it said that if you do tender, you MUST vote FOR the warrant amendment proposal which reduces the term of any and all remaining NEBU Warrants to expire upon the consummation of the Merger.  AND included in the Business Combination Agreement it stated that in order for the warrant amendment to be passed, 8,250,000 warrants of the 9,166,666 public warrants need to be validly tendered or the Seller can terminate the agreement.  Which seemed like a really high threshold to meet (90%).   Except, it’s not 90%.  It’s only 50%.

Say what now? Yes, that’s right.  If you look at Nebula’s prospectus (page 56) it states the following:

“The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants.”

That means that even though the business combination agreement stipulates a 90% threshold, it’s superseded by the warrant agreement which says that you need only 50% approval.  And for further clarification, that’s not 50% of whoever participates at the vote, but 50% of the total public warrants.  So really, Nebula needs 4,583,334 warrants to vote “Yes” on the amendment and it passes.

So now we have a bit of game theory happening again.  Regardless of however a warrant holder WANTS to vote, they have to game out how they think everyone else will vote. If you vote No, but more than 50% vote Yes, you not only do not get the $1.50, but your warrants expire at combination close. Not ideal.  Will investors tender based on the surety of $1.50 per warrant which is better than no warrant?  Hard to say.  Keep in mind that investors do talk to each other…the question is, will 50% of them have a chat?

Regardless, the 8,250,000 warrant threshold language seems like a real nightmare for the bankers who are probably having to clarify this all over the street today.  Especially since the warrants are currently trading around $1.70, far above the $1.50 tender price.  Stay tuned for further developments

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved